News Search

“This is undeniably a major advance,” said Dr. Jeffrey Lieberman. But he cautioned much is still unknown about the drug, particularly regarding its long-term use.

The FDA is set to approve SPRAVATOTM, an esketamine nasal spray that could help certain patients with severe depression. Dr. Drew Ramsey explains.

Dr. John Mann and colleagues followed 663 young adults who were at high risk for suicidal behavior because their parents had been diagnosed with mood disorders.

“When the child has not made academic progress despite accommodations, he or she can develop other challenges that negatively affect their functioning at home and at school,” says Dr. Meghan Tomb.